Psychedelics

Psychedelics in psychiatry: emerging research on psilocybin, MDMA and ketamine. Clinical evidence, treatment protocols and therapeutic potential.

Page 3

Recently published articles about Psychedelics

PCC
Medical Uses and Adverse Effects of Psilocybin
Rounds in the General Hospital

May 28, 2024

There has been a resurgence of interest in the use of psychedelics, including psilocybin, for therapeutic purposes, with early studies suggesting promise for use in various conditions such as...
, ,
Weekly Mind Reader: Exploring the Connection Between Psilocybin and Serotonin
news

March 1, 2024

The Primary Care Companion has published research that examines the relationship between psilocybin and some brain chemicals.
PCC
Psilocybin and the Development of Serotonin Toxicity
Case Report

February 29, 2024

This case revealed that unregulated and recreational use of psilocybin in the setting of polypharmacy demonstrates a potential risk for serotonin toxicity that should be diligently monitored.
, ,
PCC
Psychedelic Microdosing and Mental Health
Systematic Review

January 16, 2024

There is a growing body of evidence suggesting a positive correlation between psychedelic microdosing and improved mental well-being.
, , , et al
More Evidence Psychedelics Can Curb Depression
news

December 21, 2023

Recent research shows psilocybin effectively reduces depression in cancer patients, with promising results in therapeutic settings.
FDA Releases First-Ever Draft Guidance on Psychedelic Drug Research
news

June 26, 2023

FDA's groundbreaking guidance aims to advance psychedelic drug research and promote safety.
news

June 15, 2023

A metamorphic revolution is happening in psychiatry, led by psychedelic therapy and MDMA. Scott Aaronson, MD explores the therapeutic benefits.
PCC
Neurobiological Correlates of Psilocybin Response in MDD
Systematic Review

May 23, 2023

Transient functional brain changes with psilocybin therapy resemble the “brain reset” phenomenon and may serve as the putative predictors of psilocybin antidepressant response.
, , , et al
JCP
Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review
Systematic Review

May 10, 2023

Randomized trials of psychedelics underutilize blind assessment, active drug controls, and testing psychological support against minimal-support conditions—elements that would improve quality or provide important information.
, , , et al
Colorado Becomes Second State to Legalize Psychedelic Mushrooms
news

November 11, 2022

Colorado said yes to Proposition 122, which legalizes the medically supervised use of psilocybin.
JCP
Corrigendum to “Decreases in Suicidality Following Psychedelic Therapy: A Meta-Analysis of Individual Patient Data Across Clinical Trials”
Letter to the Editor

May 9, 2022

The authors note two suicidality-related events that occurred within the studies included in their recent meta-analysis.
, , , et al
JCP
Commentary

January 18, 2022

This commentary discusses the article by Zeifman and colleagues on the role classic psychedelic agents may have in reducing risk of suicide.
,

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe